Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service mechanical circulatory support cases in Georgia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 577 | 43% |
| 2020 | 0 | 494 | 46% |
| 2021 | 1 | 485 | 51% |
| 2022 | 1 | 495 | 54% |
| 2023 | 0 | 429 | 57% |
| 2024 | 0 | 422 | 59% |
| 2025 from claims | – | 470 380–551 | 60% |
| 2026 forecast | – | 477 374–599 | 60% |
| 2027 forecast | – | 484 359–639 | 61% |
| 2028 forecast | – | 490 347–676 | 62% |
| 2029 forecast | – | 497 337–712 | 62% |
| 2030 forecast | – | 503 329–746 | 63% |
Percutaneous ventricular assist and intra-aortic balloon pump. Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 2 | 1,476−3.6%/yr | −3.6%/yr | 0.7 | 0% | 2,210 in 2030+6.9%/yr |
| Florida | 5 | 1,323−3.5%/yr | −3.5%/yr | 0.6 | 0% | 1,380 in 2030+0.8%/yr |
| North Carolina | 1 | 534−5.9%/yr | −5.9%/yr | 0.5 | 0% | 550 in 2030+0.4%/yr |
| Tennessee | 2 | 492−1.4%/yr | −1.4%/yr | 0.7 | 0% | 420 in 2030−2.5%/yr |
| Virginia | 1 | 392−3.6%/yr | −3.6%/yr | 0.4 | 0% | 450 in 2030+2.2%/yr |
| Maryland | 5 | 360−2%/yr | −2%/yr | 0.4 | 0% | 350 in 2030−0.6%/yr |
| Louisiana | 0 | 290−8.2%/yr | −8.2%/yr | 0.7 | 0% | 300 in 2030+0.7%/yr |
| Kentucky | 0 | 264−6.4%/yr | −6.4%/yr | 0.6 | 0% | 220 in 2030−2.9%/yr |
| South Carolina | 0 | 256−4.4%/yr | −4.4%/yr | 0.4 | 0% | 300 in 2030+2.7%/yr |
| Alabama | 1 | 254−13%/yr | −13%/yr | 0.6 | 0% | 240 in 2030−1.3%/yr |
| Arkansas | 0 | 234−12%/yr | −12%/yr | 0.6 | 0% | 250 in 2030+1.1%/yr |
| Oklahoma | 0 | 231−9.9%/yr | −9.9%/yr | 0.5 | 0% | 240 in 2030+0.7%/yr |
| Mississippi | 0 | 161−10%/yr | −10%/yr | 0.4 | 0% | 180 in 2030+1.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 147 | 6,267−8%/yr | −8%/yr | 5.81.0× | 0% | 7,490 in 2030+3%/yr |
| Structural heart (TAVR, TEER) | 72 | 1,794+2.7%/yr | +2.7%/yr | 1.71.1× | 0% | 2,890 in 2030+8.3%/yr |
Mechanical circulatory support in every state, and its device makers · Every procedure market in Georgia · Every state · Compare with Texas
Briohealth Solutions leads with 84% of company spending on these surgeons in 2025, +84 pts on 2024.
In 2025, 4 companies reported engagement with Georgia’s surgeons worth $8,217 in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.